Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial

Solomiia Potsiurko, Dmytro Dobryanskyy, Lesya Sekretar, Solomiia Potsiurko, Dmytro Dobryanskyy, Lesya Sekretar

Abstract

Background: Patent ductus arteriosus (PDA) is a common complication in very preterm infants. It is known that there is an association between PDA and development of bronchopulmonary dysplasia (BPD) or death before the postmenstrual age (PMA) of 36 weeks, but this association remains one of the most controversial aspects of the problem. The study aimed to evaluate the relationship between PDA, serum NT-proBNP levels at 2-3 and 8-9 days of life, and BPD/death in very preterm infants.

Methods: Data of 52 preterm infants with a gestational age < 32 weeks, chronological age < 72 h, and PDA diameter > 1.5 mm, enrolled in a randomized controlled trial, were used for the retrospective analysis. All patients underwent daily echocardiographic and two serum NT-proBNP measurements within the first 10 days after birth. Two groups of infants were formed retrospectively at PMA of 36 weeks depending on the outcome, BPD (n = 18)/death (n = 7) or survival without BPD (n = 27). Receiver operator characteristic (ROC) curve was used to evaluate the predictive performance of serum NT-proBNP levels for BPD/death occurrence.

Results: The percentage of infants who received pharmacological treatment for PDA did not differ between the groups. Based on the area under the ROC curve, serum NT-proBNP levels on the 2-3 day of life (AUC = 0.71; 95% confidence interval (CI): 0.56-0.9; p = 0.014)) and on the 8-9 day of life (AUC = 0.76; 95% CI: 0.6-0.9; p = 0.002) could reliably predict BPD/death in very preterm infants who had PDA diameter > 1.5 mm in the first 72 h of life. Hemodynamically significant PDA (hsPDA) was significantly more often detected in newborns with BPD/death, however, treatment of infants with hsPDA did not reduce the incidence of BPD/death.

Conclusions: In very preterm infants with PDA > 1.5 mm at the age of 24-48 h, serum NT-proBNP concentration could reliably predict the development of BPD or death, regardless of the persistence of PDA, with the highest diagnostic value at 8-9 days.

Trial registration: This study is registered in ClinicalTrials.gov - NCT03860428 on March 4, 2019.

Keywords: Bronchopulmonary dysplasia, hemodynamically significant patent ductus arteriosus; NT-proBNP; Prognostic value.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of study patients. BPD = bronchopulmonary dysplasia; NT-proBNP = N-terminal pro-brain natriuretic peptide; PDA = patent ductus arteriosus
Fig. 2
Fig. 2
ROC-curves describing N-terminal pro-brain natriuretic peptide cut-off values for the prediction of BPD/death at the median age of 2 and 8 days in very preterm infants with PDA (the first measurement - 2-3 days of life; the second measurement - 8-9 days of life)

References

    1. Sung SI, Chang YS, Chun JY, Yoon SA, Yoo HS, Ahn SY, et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr. 2016;177:66–71.e1. doi: 10.1016/j.jpeds.2016.06.046.
    1. Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F, Fumagalli M. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr. 2015;166(6):1488–1492. doi: 10.1016/j.jpeds.2015.03.012.
    1. Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Høst B, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98(6):F505–F510. doi: 10.1136/archdischild-2013-303816.
    1. Willis KA, Weems MF. Hemodynamically significant patent ductus arteriosus and the development of bronchopulmonary dysplasia. Congenit Heart Dis. 2019;14(1):27–32. doi: 10.1111/chd.12691.
    1. Clyman RI, Hills NK, Liebowitz M, Johng S. Relationship between duration of infant exposure to a moderate-to-large patent Ductus Arteriosus shunt and the risk of developing Bronchopulmonary dysplasia or death before 36 weeks. Am J Perinatol. 2020;37(2):216–223. doi: 10.1055/s-0039-1697672.
    1. Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2019;6:CD004213. doi: 10.1002/14651858.CD004213.pub4.
    1. Farooqui MA, Elsayed YN, Jeyaraman MM, Dingwall O, Tagin M, Zarychanski R. Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: a systematic review and meta-analysis. J Neonatal Perinatal Med. 2019;12(1):1–7. doi: 10.3233/NPM-17130.
    1. Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41–8.e6. doi: 10.1016/j.jpeds.2018.09.012.
    1. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014;100(3):145–157. doi: 10.1002/bdra.23235.
    1. Rivera L, Siddaiah R, Oji-Mmuo C, Silveyra GR, Silveyra P. Biomarkers for Bronchopulmonary dysplasia in the preterm infant. Front Pediatr. 2016;4:33. doi: 10.3389/fped.2016.00033.
    1. Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics. 2015;135(2):e510–e525. doi: 10.1542/peds.2014-1995.
    1. Rodríguez-Blanco S, Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Palau-Benavides M. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: a prospective observational study. Pediatr Pulmonol. 2018;53(8):1073–1081. doi: 10.1002/ppul.24053.
    1. Xiong T, Kulkarni M, Gokulakrishnan G, Shivanna B, Pammi M. Natriuretic peptides in bronchopulmonary dysplasia: a systematic review. J Perinatol. 2020;40(4):607–615. doi: 10.1038/s41372-019-0588-2.
    1. Hundscheid T, Onland W, van Overmeire B, Dijk P, van Kaam AHLC, Dijkman KP, Kooi EMW, Villamor E, Kroon AA, Visser R, Vijlbrief DC, de Tollenaer SM, Cools F, van Laere D, Johansson AB, Hocq C, Zecic A, Adang E, Donders R, de Vries W, van Heijst AFJ, de Boode WP. Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial) BMC Pediatr. 2018;18(1):262. doi: 10.1186/s12887-018-1215-7.
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–1729. doi: 10.1164/ajrccm.163.7.2011060.
    1. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23(6):451–456. doi: 10.1038/sj.jp.7210963.
    1. Arlettaz R. Echocardiographic evaluation of patent Ductus Arteriosus in preterm infants. Front Pediatr. 2017;5:147. doi: 10.3389/fped.2017.00147.
    1. Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr. 2012;101(3):247–251. doi: 10.1111/j.1651-2227.2011.02468.x.
    1. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risks cores. J Pediatr. 2001;138(1):92–100. doi: 10.1067/mpd.2001.109608.
    1. Clyman R. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol. 2013;37(2):102–107. doi: 10.1053/j.semperi.2013.01.006.
    1. Härkin P, Marttila R, Pokka T, Saarela T, Hallman M. Morbidities associated with patent ductus arteriosus in preterm infants. Nationwide cohort study. J Matern Fetal Neonatal Med. 2018;31(19):2576–2583. doi: 10.1080/14767058.2017.1347921.
    1. Smith A, El-Khuffash A. Defining “Haemodynamic significance” of the patent Ductus Arteriosus: do we have all the answers? Neonatology. 2020;117(2):1–8. doi: 10.1159/000506988.
    1. El-Khuffash A, James AT, Corcoran JD, Dicker P, Franklin O, Elsayed YN, et al. A patent ductus arteriosus severity score predicts chronic lung disease or death before discharge. J Pediatr. 2015;167(6):1354–1361.e2. doi: 10.1016/j.jpeds.2015.09.028.
    1. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F424–F427. doi: 10.1136/adc.2007.118117.
    1. Mirza H, Garcia J, McKinley G, Hubbard L, Sensing W, Schneider J, Oh W, Wadhawan R. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants. J Perinatol. 2019;39(12):1648–1655. doi: 10.1038/s41372-019-0496-5.
    1. Wai KC, Kohn MA, Ballard RA, Truog WE, Black DM, Asselin JM, et al. Early cumulative supplemental oxygen predicts bronchopulmonary dysplasia in high risk extremely low gestational age newborns. J Pediatr. 2016;177:97–102.e2. doi: 10.1016/j.jpeds.2016.06.079.
    1. Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Rodríguez-Blanco S. Early assessment of lung aeration using an ultrasound score as a biomarker of developing bronchopulmonary dysplasia: a prospective observational study. J Perinatol. 2021;41(1):62–68. doi: 10.1038/s41372-020-0724-z.
    1. Harris SL, More K, Dixon B, Troughton R, Pemberton C, Horwood J, Ellis N, Austin N. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr. 2018;177(4):521–532. doi: 10.1007/s00431-018-3089-y.
    1. Zhou L, Xiang X, Wang L, Chen X, Zhu J, Xia H. N-terminal pro-B-type natriuretic peptide as a biomarker of Bronchopulmonary dysplasia or death in preterm infants: a retrospective cohort analysis. Front Pediatr. 2019;7:166. doi: 10.3389/fped.2019.00166.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi